Prehospital GFAP and UCH-L1 Testing for Identification of Intracerebral Hemorrhage Versus Acute Ischemic Stroke and Stroke Mimics in Suspected Stroke.
The NeuroPOCT-Stroke Pilot Study is a prospective prehospital diagnostic accuracy and feasibility study investigating whether the brain injury biomarkers GFAP and UCH-L1 can be measured directly in the ambulance and help distinguish intracerebral hemorrhage (ICH) from acute ischemic stroke (AIS) and stroke mimics.
GFAP and UCH-L1 are measured from a small whole-blood sample using the Abbott i-STAT Alinity point-of-care platform. The study is conducted in six ambulances in the Central Denmark Region and is expected to include approximately 1,000 adult patients with suspected stroke.
The biomarker results are collected for research purposes only and do not influence clinical assessment, treatment, triage, or transport. Patients continue to receive standard prehospital and hospital care independently of the study results.
Stroke is a time-critical condition, but in the prehospital setting it is currently difficult to distinguish a brain hemorrhage from an ischemic stroke before brain imaging is performed at the hospital. This distinction is important because the underlying conditions require different treatment strategies.
GFAP is a protein found primarily in supporting cells of the brain and is released into the blood following certain types of brain injury. Previous research suggests that GFAP may be particularly useful for identifying intracerebral hemorrhage early after symptom onset. UCH-L1 is another brain injury biomarker that may provide additional diagnostic information when measured alongside GFAP.
Until recently, most research on these biomarkers has been performed after patients arrive at the hospital. Portable point-of-care technology now makes it possible to measure GFAP and UCH-L1 from whole blood in the prehospital setting. This study therefore investigates both how well the biomarkers distinguish different causes of suspected stroke and whether testing can be integrated into routine ambulance workflows.
Patients with suspected stroke who are attended by one of the participating study ambulances may be included. A small blood sample is collected and analysed for GFAP and UCH-L1 using the i-STAT Alinity.
For patients transported to Aarhus University Hospital, an additional blood sample is collected for laboratory-based biomarker analyses. These samples allow the researchers to compare the prehospital point-of-care measurements with more advanced laboratory measurements.
The patient's final hospital diagnosis and relevant imaging results are subsequently used to evaluate how accurately the prehospital biomarkers distinguish intracerebral hemorrhage from ischemic stroke and stroke mimics.
This pilot study does not use the biomarker results to make clinical decisions. Instead, it will provide the evidence needed to determine whether biomarker-guided prehospital stroke care should be investigated in future clinical trials.
If prehospital biomarkers can reliably identify patients with intracerebral hemorrhage at an early stage, they could potentially support more targeted prehospital management strategies in the future.